| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
|
Purity: ≥98%
Boceprevir (previously known as EBP 520; SCH 503034; trade name: Victrelis) is a novel, orally bioavailable, selective, direct acting inhibitor of hepatitis C virus (HCV) protease with Ki value of 14 nM for NS3 in an enzyme assay and EC90 of 350 nM in cell-based replicon assay. It is an FDA approved drug (trade name: Victrelis) used in combination with other antiviral agents for the treatment of chronic hepatitis C, genotype 1. It exerts the effects by binding to the nonstructural 3 NS3 (HCV) active site of HCV.
| Targets |
HCV NS3 protease(Ki=14 nM)
|
|---|---|
| ln Vitro |
The potency of boceprevir (SCH 503034) in the HCV NS3 protease continuous assay is 14 nM (Ki) on average over a high number of runs. The EC50 and EC90 values in the HuH-7 cells bicistronic subgenomic cell-based replicon assay are found to be 0.20 µM and 0.35 µM, respectively. The assay lasts for 72 hours. Additionally, it is discovered that boceprevir has a selectivity of 2200 and is a very weak inhibitor of HNE (Ki=26 µM)[1].
|
| ln Vivo |
An HCV protease inhibitor called boceprevir is used to treat hepatitis C virus infection. Boceprevir's pharmacokinetic profile is assessed in a variety of animal species. After being given orally, rats (10 mg/kg), dogs (3 mg/kg), and monkeys (3 mg/kg) absorb boceprevir moderately. The mean absorption times (MAT) of mice (10 mg/kg), rats, and monkeys show that while absorption is relatively fast in dogs, it is slower in these animals. In dogs and rats, the AUC is good; in mice, it is moderate; and in monkeys, it is low. In mice, rats, and dogs (26-34%), the absolute oral bioavailability is moderate, but in monkeys (4%) it is low[1]. Triple-transgenic mice treated with boceprevir (100 mg/kg) showed reduced HCV NS3/4A protease activity[2].
|
| Animal Protocol |
Mice
MedChem Express is the source for boceprevir purchases. Triple-transgenic mice (n = 5 per group) are induced with Doxycycline (Dox) for 10 days in order to assess the impact of Boceprevir. The mice receive oral gavage twice daily for seven days with either Boceprevir (100 mg/kg) or DMSO after plasma Gluc activity peaks on the third day following Dox induction. Every day during this time, blood is drawn from the caudal vein in order to measure plasma Gluc activity. |
| References |
|
| Molecular Formula |
C27H45N5O5
|
|---|---|
| Molecular Weight |
519.68
|
| Exact Mass |
519.34
|
| Elemental Analysis |
C, 62.40; H, 8.73; N, 13.48; O, 15.39
|
| CAS # |
394730-60-0
|
| Related CAS # |
Boceprevir-d9;1256751-11-7
|
| Appearance |
Off-white to pale yellow solid powder
|
| SMILES |
O=C([C@@H]1[C@@]2([H])C(C)(C)[C@@]2([H])CN1C([C@@H](NC(NC(C)(C)C)=O)C(C)(C)C)=O)NC(C(C(N)=O)=O)CC3CCC3
|
| InChi Key |
LHHCSNFAOIFYRV-DOVBMPENSA-N
|
| InChi Code |
InChI=1S/C27H45N5O5/c1-25(2,3)20(30-24(37)31-26(4,5)6)23(36)32-13-15-17(27(15,7)8)18(32)22(35)29-16(19(33)21(28)34)12-14-10-9-11-14/h14-18,20H,9-13H2,1-8H3,(H2,28,34)(H,29,35)(H2,30,31,37)/t15-,16?,17-,18-,20+/m0/s1
|
| Chemical Name |
(1R,2S,5S)-N-(4-amino-1-cyclobutyl-3,4-dioxobutan-2-yl)-3-((S)-2-(3-(tert-butyl)ureido)-3,3-dimethylbutanoyl)-6,6-dimethyl-3-azabicyclo[3.1.0]hexane-2-carboxamide
|
| Synonyms |
EBP 520; EBP-520; EBP520; SCH-503034; SCH503034; SCH 503034; trade name: Victrelis.
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 16.67 ~100 mg/mL ( 32.08~192.42 mM )
H2O : < 0.1 mg/mL Ethanol : ~100 mg/mL |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.67 mg/mL (3.21 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 1.67 mg/mL (3.21 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 16.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 1.67 mg/mL (3.21 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. Solubility in Formulation 4: 10% DMSO+40% PEG300+5% Tween-80+45% Saline: ≥ 1.67 mg/mL (3.21 mM) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.9243 mL | 9.6213 mL | 19.2426 mL | |
| 5 mM | 0.3849 mL | 1.9243 mL | 3.8485 mL | |
| 10 mM | 0.1924 mL | 0.9621 mL | 1.9243 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
|
|
|
|
|
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA
